Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

References

• MoeSMDrüekeTLameireNEknoyanGChronic kidney disease-mineral-bone disorder: a new paradigmAdv Chronic Kidney Dis200714131217200038
   PubMed Web of Science ®Google Scholar
• RodriguezMNemethEMartinDThe calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidismAm J Physiol Renal Physiol20052882F253F26415507543
   PubMed Web of Science ®Google Scholar
• FoleyRNParfreyPSSarnakMJClinical epidemiology of cardiovascular disease in chronic renal diseaseAm J Kidney Dis1998325 Suppl 3S112S1199820470
   PubMed Web of Science ®Google Scholar
• Kalantar-ZadehKKuwaeNRegidorDLSurvival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney Int200670477178016820797
   PubMed Web of Science ®Google Scholar
• BlockGAKlassenPSLazarusJMOfsthunNLowrieEGChertowGMMineral metabolism, mortality, and morbidity in maintenance hemodi-alysisJ Am Soc Nephrol20041582208221815284307
   PubMed Web of Science ®Google Scholar
• LowrieEGLairdNMParkerTFSargentJAEffect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis StudyN Engl J Med198130520117611817027040
   PubMed Web of Science ®Google Scholar
• OwenWFLewNLLiuYLowrieEGLazarusJMThe urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysisN Engl J Med199332914100110068366899
   PubMed Web of Science ®Google Scholar
• LowrieEGLewNLDeath risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilitiesAm J Kidney Dis19901554584822333868
   PubMed Web of Science ®Google Scholar
• CollinsAJMaJZEbbenJImpact of hematocrit on morbidity and mortalitySemin Nephrol200020434534910928336
   PubMed Web of Science ®Google Scholar
• AndressDLVitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activationKidney Int2006691334316374421
   PubMed Web of Science ®Google Scholar
• CozzolinoMKettelerMZehnderDThe vitamin D system: a crosstalk between the heart and kidneyEur J Heart Fail201012101031104120605845
   PubMed Web of Science ®Google Scholar
• MartinKJGonzálezEAMetabolic bone disease in chronic kidney diseaseJ Am Soc Nephrol200718387588517251386
   PubMed Web of Science ®Google Scholar
• DussoASBrownAJSlatopolskyEVitamin DAm J Physiol Renal Physiol20052891F8F2815951480
   PubMed Web of Science ®Google Scholar
• IfuduOCare of patients undergoing hemodialysisN Engl J Med199833915105410629761808
   PubMed Web of Science ®Google Scholar
• GoodmanWGGoldinJKuizonBDCoronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysisN Engl J Med2000342201478148310816185
   PubMed Web of Science ®Google Scholar
• MillinerDSZinsmeisterARLiebermanELandingBSoft tissue calcification in pediatric patients with end-stage renal diseaseKidney Int19903859319362266678
   PubMed Web of Science ®Google Scholar
• MallickNPBerlyneGMArterial calcification after vitamin-D therapy in hyperphosphatemic renal failureLancet196827582131613204177388
   PubMed Web of Science ®Google Scholar
• TengMWolfMLowrieEOfsthunNLazarusJMThadhaniRSurvival of patients undergoing hemodialysis with paricalcitol or calcitriol therapyN Engl J Med2003349544645612890843
   PubMed Web of Science ®Google Scholar
• HansenDRasmussenKDanielsenHNo difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trialKidney Int201180884185021832979
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• WellsGSheaBO’ConnellDPetersonJWelchVThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses3rd Symposium on Systematic Reviews: Beyond the BasicsOttawa, ON CanadaUniversity of Ottawa200035
   Google Scholar
• HigginsJPAltmanDGGotzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst195922471974813655060
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• IzquierdoMJCaviaMMuñizPParicalcitol reduces oxidative stress and inflammation in hemodialysis patientsBMC Nephrol20121315923186077
   PubMed Web of Science ®Google Scholar
• CozzolinoMKettelerMMartinKJSharmaAGoldsmithDKhanSParicalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT studyNephrol Dial Transplant201429489990524500308
   PubMed Web of Science ®Google Scholar
• AfsarBAgcaETurkSComparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitolJ Clin Pharmacol201555111280128526032009
   PubMed Web of Science ®Google Scholar
• Oliva-DamasoEOliva-DamasoNRodriguez-EsparragonFAsymmetric dimethylarginine (ADMA) levels are lower in hemodialysis patients treated with paricalcitolKidney Int Rep20172216517129142954
   PubMed Web of Science ®Google Scholar
• MillerJEMolnarMZKovesdyCPAdministered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysisPharmacoepidemiol Drug Saf201221111232123922996597
   PubMed Web of Science ®Google Scholar
• FernströmAGiæverJGranrothBAchievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational studyScand J Urol Nephrol201145319620521366390
   PubMed Web of Science ®Google Scholar
• HansenDBrandiLRasmussenKTreatment of secondary hyper-parathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidolBMC Nephrol2009102819778452
   PubMed Web of Science ®Google Scholar
• CozzolinoMBrancaccioDCannellaGFARO Study GroupVDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤150 pg/mL: results of the Italian FARO SurveyNephrol Dial Transplant20122793588359422523119
   PubMed Web of Science ®Google Scholar
• FarhatKStavenuiterAWDVervloetMGTer WeePMBeelenRHJvan IttersumFJEffects of oral paricalcitol and calcitriol treatment on peritoneal membrane characteristics of peritoneal dialysis patients – a pilot studyPerit Dial Int201838322022829386308
   PubMed Web of Science ®Google Scholar
• TentoriFHuntWCStidleyCAMedical Directors of Dialysis Clinic IncMortality risk among hemodialysis patients receiving different vitamin D analogsKidney Int200670101858186517021609
   PubMed Web of Science ®Google Scholar
• ShinabergerCSKoppleJDKovesdyCPRatio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patientsClin J Am Soc Nephrol2008361769177618701614
   PubMed Web of Science ®Google Scholar
• Abdul GaforAHSaidinRLooCYIntravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperpara-thyroidismNephrology (Carlton)200914548849219298641
   PubMed Web of Science ®Google Scholar
• AkizawaTAkibaTHirakataHComparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidismTher Apher Dial201519322523425363733
   PubMed Web of Science ®Google Scholar
• Večerić-HalerŽRomoziKAntoničMComparison of the pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis populationTher Apher Dial201620326126627312912
   PubMed Web of Science ®Google Scholar
• OngLMNarayananPGohHKOral Paricalcitol in ESRD Study GroupRandomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidismNephrology (Carlton)201318319420023311404
   PubMed Web of Science ®Google Scholar
• JamaluddinEJGaforAHYeanLCOral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidismClin Exp Nephrol201418350751423903802
   PubMed Web of Science ®Google Scholar
• KettelerMMartinKJWolfMParicalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperpara-thyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyNephrol Dial Transplant20122783270327822387567
   PubMed Web of Science ®Google Scholar
• SpragueSMLermaEMcCormmickDAbrahamMBatlleDSuppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriolAm J Kidney Dis2001385 Suppl 5S51S56
   PubMed Web of Science ®Google Scholar